Study Enrollment

Your details will not be published or shared.

Clinical Trial

RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants Born prematurely With retinopathy of prematurity

This is a clinical research study to find out if ranibizumab (brand name Lucentis®) is safe and has beneficial effects in the treatment of retinopathy of prematurity (ROP), a condition of abnormal blood vessel (arteries and veins) development in the eyes of premature babies.

Eligibility Criteria

  • premature infants with diagnosed ROP

Contact Information

    Jatinder Bhatia, MD

    706 721-2331